THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis) — FRAMES  

Cirrhosis Clinical Trial

Official title: Identification of Clinical and Biological Factors Determining Disease Severity and Disease Progression in NAFLD: "THE FRENCH NATIONAL NAFLD COHORT" FRAMES (FRench pAtients With MEtabolic Steatosis)

Status Not yet recruiting

Clinical Trial Summary

The main objective of this cohort study is to determine genetic, clinical biologic and metabolic factors associated with patient heterogeneity in regards to severity of NAFLD at diagnosis as well as during the clinical course.

• at diagnosis, with the aim to better characterize patients of different severity and improve our understanding of clinical and histological heterogeneity at diagnosis

• during the clinical course to better understand and predict disease progression in terms notably of fibrosis progression and progression to cirrhosis

Clinical Trial Description

Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome and is currently the most common cause of liver disease in many developed countries worldwide.

The aim of the study is to improve the scientific knowledge on markers associated with disease severity and progression in NAFLD.

The study is a multicentre French NAFLD cohort of well-characterized patients with biological samples covering the entire spectrum of NAFLD severity (steatosis, NASH, significant fibrosis, cirrhosis, hepatocellular carcinoma). ;

Related Conditions & MeSH terms

• Cirrhosis
• Fatty Liver
• Fibrosis
• NAFLD
• NASH
• NASH - Nonalcoholic Steatohepatitis
• Non-alcoholic Fatty Liver Disease

• NCT number: NCT04925362
• Study type: Interventional
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Vlad RATZIU
• Phone: 0142161001
• Email: vlad.ratziu@aphp.fr
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 2021
• Completion date: June 2036